Clinical Trials Logo

Disseminated Neuroblastoma clinical trials

View clinical trials related to Disseminated Neuroblastoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02173093 Recruiting - Clinical trials for Recurrent Neuroblastoma

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them. This bispecific antibody recognizes GD2, a protein found on almost all neuroblastoma and osteosarcoma cells. The investigators put the GD2 bispecific antibody on T cells and give large numbers of these T cells back to patients. The investigators think that these T cells may have a better chance of killing GD2 expressing tumor cells when they are armed with GD2 bispecific antibody. This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neuroblastoma, osteosarcoma, and other GD2-positive solid tumors.